RecruitingNCT04517838

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Immune Response to Anti-HER2 Therapies

Sponsor

Mayo Clinic

Enrollment

230 participants

Start Date

Jul 31, 2020

Study Type

OBSERVATIONAL

Conditions

Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Anatomic Stage I Breast Cancer AJCC v8 Breast Adenocarcinoma HER2-Positive Breast Carcinoma

Summary

This study gathers information from the blood cells and tumor tissue during treatment with anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib, in patients with HER2 positive stage I-IV breast cancer who are scheduled to start anti-HER2 therapy. The information gained from this study may help researchers better understand the relation between cell response and anti-HER2 therapies.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how the immune system responds to anti-HER2 treatments (such as trastuzumab/Herceptin) in patients with HER2-positive breast cancer, with the goal of better understanding why some patients respond better than others. **You may be eligible if...** - You are 18 or older - You have been diagnosed with breast cancer (any stage I through IV) that tests HER2-positive - You are starting or already receiving HER2-targeted therapy **You may NOT be eligible if...** - Your breast cancer is not HER2-positive - You have conditions that prevent blood sample collection or study participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBiospecimen Collection

Undergo collection of blood and tumor tissue samples

Locations(1)

Mayo Clinic in Florida

Jacksonville, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04517838

Related Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377479 locations

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

NCT06058377533 locations

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

NCT053791531 location

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

NCT065383891 location

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

NCT0360696730 locations